Human Rotavirus Vaccine Market Overview
Human Rotavirus Vaccine Market Size was valued at USD 10.41 Billion in 2023. The Global Human Rotavirus Vaccine industry is projected to grow from USD 11.30 Billion in 2024 to USD 19.97 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.54% during the forecast period (2024 - 2032).
Rotavirus vaccine is used to gain a shield and protect against rotavirus infections which cause severe diarrhea among young children as a part of the population. The market symptoms of rotavirus infection are inclusive of severe diarrhea, vomiting, fever, and abdominal pain which can result in disease. The Rotavirus vaccine is administered by mouth and requires two or three doses starting around six weeks of age. The vaccine first became available and gained major momentum in the United States in 2006.
COVID 19 Analysis
The human rotavirus vaccine market has been one of the affected markets since the coronavirus infection has turned into a pandemic and is facing adversities ever since. The changing way of life and inclinations of individuals is a consequence of the pandemic that sped up a significant change in the useful examples of the market. The primary explanation for this is that the pandemic has introduced significant difficulties for industry and market verticles which are confronting issues to work. The inaccessibility of unrefined substance for the creation and assembling close by the strategic help nonattendance is pushing for a mass disturbance of the store network instrument. The examples of interest and assembling are distinctive in both the provincial and worldwide areas are vigorously affecting the capacity of the interest to work and the practical limitations that have been forced are likewise adding to the affliction.
Notwithstanding, to accomplish the past examples and advantage both the makers and interest groups, the public authority is putting resources into innovative work strategies to assist the market with growing a worldwide scale. Likewise, the key market players are en route to curating inventive and imaginative items and dispatching them for an enormous scope. This is being done to assist them with perceiving the items and requests according to the accessibility likewise.
Market Dynamics
Drivers
Some major factors are projected to promote the growth of the Human Rotavirus Vaccine Market size in the forecast period that will be ending in 2028. The factors contributing to the growth of the human rotavirus vaccine market include increased development alongside an increase in the number of people with weakened immunity. Also, the market is witnessing an increase in public awareness which has positive attributes in store for the global market during the ongoing forecast period that will be ending in 2028. Also, there has been a substantial increase in the older chunk population, as well as the general population and live births taking place. These are all aspects that are driving the Human Rotavirus Vaccine Market forward as per the predictions that have been made for the forecast period of 2021-2028.
Restraints
But, the human rotavirus therapeutics market is witnessing a substantial decrease in healthcare expenses in most of the advancing countries. This is one of the major reasons that is restraining the human rotavirus vaccine market from growing during the forecast period that will be ending in 2028. The human rotavirus vaccine market is further, witnessing a rise in the prices of the vaccines and the adverse reactions alongside the increased side effects of the vaccine that are further estimated to bar the human rotavirus vaccine market shortly, as a part of the ongoing forecast period of 2021-2028.
Technology Analysis
The rise in the production scales of the vaccines is escalating the growth of the human rotavirus vaccine market as per the predictions of the experts for the forecast period of 2021-2028. Rotavirus vaccine is known to be applied to gain prevention against rotavirus infections which can cause severe diarrhea that is more prevalent amongst young children. The symptoms of rotavirus infection are inclusive of severe diarrhea, and other issues like vomiting, fever, and abdominal pain. These issues can cause disease and harm the health of the global target audience. Rotavirus vaccine is given through the mouth and requires a minimum of two or three doses starting around six weeks of age amongst the youngsters.
Study Objectives
- To have significant market experiences and outline close by the perspectives as advanced by the business chiefs and specialists to foresee the CAGR pace of development of the human rotavirus vaccine market and the market valuation during 2021-2028
- To concentrate on the extent of the market during the estimated time frame by seeing the market patterns and fragment execution in major geological locales of the globe. The market report aims to have a deep understanding based on which the human rotavirus vaccine market has been segmented. The report further helps to understand the potential of the market segments to meet the rising needs of the people and help the market players understand the demand patterns so that they can produce and manufacture accordingly.
- To have an outline of the serious degree winning in the market among the key market players during the period and break down the new improvements attempted by the local players for worldwide rivalry and competition amid the market operations that are at different stages of completion during the ongoing forecast period that will be ending in 2028.
Human Rotavirus Vaccine Market Segment
The human rotavirus vaccine market revenue is rising because of the excellent performance of the following market segments. They are:
Based on the market type
The human rotavirus vaccine market is segmented based on the market type and includes Rotarix, RotaTeq, rotavac, rotavin-M1, Lanzhou lamb, amongst others.
Based on the market application
The human rotavirus vaccine market is segmented based on the market applications and includes Hospitals and Clinics, Academic and Research centers.
Based on the market end-users
The human rotavirus vaccine market is segmented based on the market end-users and includes the demand from pediatricians, gynecologists, and others.
Regional Analysis
The North American region is likely to dominate the human rotavirus vaccine market. The main reason behind this is the widespread utilization of medications and an increase in the expenses of health care. Further, the human rotavirus vaccine market analysis shows that there is a rapid uptake of new technology and the focus of main research companies. Also, the vaccine research sector in the advanced economies will further boost the growth of the human rotavirus vaccine market trends in the region during the forecast period that will be ending in 2028.
Competitive Landscape
The human rotavirus vaccine market share is rising because of the performance of the following market players:
- Bharat Biotech
- Serum Institute of India Pvt. Ltd.
- GlaxoSmithKline plc.
- Merck & Co., Inc.
- BIOVIRx Inc.
- Sanofi
- Lanzhou Institute of Biologicals Products Co., Ltd.
Recent Developments
- The World Health Organization (WHO) has recommended that the rotavirus vaccine should be included in national routine vaccinations programs. The human neonatal rotavirus is responsible for the prevention of 15 to 34% of severe diarrhea in the developing world economies and 37 to 96% related to severe diarrhea in the developed world economies that are a part of the global human rotavirus vaccine market. According to World Health Organization (WHO), in one of the global countries - Mexico, a decline of up to 50% in diarrhoeal deaths in children who belong to the age group of fewer than 5 years of age was attributed directly to the use of the vaccine and safeguard their health.
- There has been an upsurge in the disposable income and the initiatives taken by the government that is belonging to the APAC region, as a part of the market, is anticipated to propel at a great growth rate of the human rotavirus vaccine market in the region in the coming years, as a part of the forecast period that will be ending in 2028.
- The research and developments have been on the rise in the European region that will help the market to expand as per the predictions for the forecast period of 2021-2028.
Intended Audience
- Global Human rotavirus vaccine treatment manufacturers, wholesalers, dealers, and suppliers
- Research and development (R&D) firms, groups, and companies
- Vaccine importers and exporters
- Hospitals, healthcare centers, and clinics
- Academic institutions and universities
Report Overview
The human rotavirus vaccine market report is a combination of the diverse market factors that will help the market and lead the way towards the growth scale that has been predicted by the experts for the forecast period of 2024-2032. The human rotavirus vaccine market report helps in understanding the recent developments that have been undertaken by the industry and the ones that will lead to expansion in the ongoing forecast period that will be ending in 2023.
Report Attribute/Metric
|
Details
|
  Market Size
|
  19.97 Billion
|
  CAGR
|
 6.54%
|
  Base Year
|
  2021
|
  Forecast Period
|
  2024-2032
|
  Historical Data
|
  2020
|
  Forecast Units
|
  Value (USD Billion)
|
  Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
  Segments Covered
|
Type and End Users
|
  Geographies Covered
|
North America, Europe, Asia-Pacific, and Rest of the World (RoW)
|
  Key Vendors
|
Bharat Biotech, Merck & Co., Inc., GlaxoSmithKline plc., Multinational pharmaceutical drug company and others.
|
  Key Market Opportunities
|
The Americas account for a significant market share owing to extensive use of medications and high expenditure on the health care
Europe is the second largest market in the world due to high income and healthcare penetration.
|
  Key Market Drivers
|
HIV/AIDS patients
Growing number of immunity-compromised individuals
Increasing geriatric population
Growing population and live births
|
Frequently Asked Questions (FAQ) :
Human rotavirus vaccine market CAGR would be 6.54% during the forecast period 2024-2032.
The players involved in the human rotavirus vaccine market are Merck & Co., Inc., Multinational pharmaceutical drug company, GlaxoSmithKline plc., Bharat Biotech, and others.
Human rotavirus vaccine market report includes academic and research, hospitals & clinics, and others.
The types included in the human rotavirus vaccine market are RotaTeq, Rotavac, Rotarix, Lanzhou lamb, Rotavin-M1, and others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report